TY - JOUR ID - 8139 TI - The Evaluation of Deferasirox on Hematological Parameters after Lead Administration JO - Asia Pacific Journal of Medical Toxicology JA - APJMT LA - en SN - 2322-2611 AU - Zahmati, Maliheh AU - Shokooh Saljooghi, Amir AD - Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran Y1 - 2016 PY - 2016 VL - 5 IS - 4 SP - 124 EP - 129 KW - Deferasirox KW - Hematological Tests KW - Iron-Deficiency KW - lead poisoning DO - 10.22038/apjmt.2016.8139 N2 - Background: Metals such as iron, zinc, and copper are critical and necessary for the survival of all living organisms, whereas xenobiotic metals such as lead, cadmium, mercury, and arsenic have no known biologic role. Any metals in high doses can have toxic effects. The aim of this work was to evaluate the hematological changes induced by lead as a toxic metal and characterize the potential efficacy of Deferasirox in removing lead from bodies of male rats. Methods: Lead was given to rats at two doses of 40 (low dose of drinking lead) and 80 mg/kg (high dose of drinking lead). After 60 days of lead administration, chelation therapy was carried out for two weeks and then clinical, biochemical and haematological parameters were compared with the lead-free control group. Results: The results showed a decrease in iron level, hematocrit, red blood cells count, hemoglobin concentration, mean cellular volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration, after lead administration. Chelation therapy with Deferasirox (DFX) significantly reduced blood lead level, and iron concentrations returned to normal levels simultaneously. Conclusion: Deferasirox significantly reduced blood lead level along with normalizing iron. The symptoms of toxicity were also reduced and iron deficiency anemia following lead administration was obviated. UR - https://apjmt.mums.ac.ir/article_8139.html L1 - https://apjmt.mums.ac.ir/article_8139_05a575e0990fba715383750e046adae8.pdf ER -